U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug
© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo AMGN -2.85% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully to:
+ Add another position Close JNJ +0.89% Add to/Remove from Watchlist Add to Watchlist Add Position
Position added successfully to:
+ Add another position Close
(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Amgen (NASDAQ:AMGN)'s biosimilar version of Johnson & Johnson (NYSE:JNJ)'s blockbuster psoriasis treatment, Stelara, for multiple inflammatory diseases.
Despite the FDA approval, Amgen's treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.
Biosimilars are close copies of complex biological drugs.
Stelara, introduced in 2009, has been J&J's top-selling drug since 2019, with sales reaching $9.7 billion in 2022.
U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug
Asian stocks sink as rate cut rally cools, weak economic data weighs
Top development banks, funds set up 'debt-for-nature' task force
China's Nov services activity accelerates on boost from new orders - Caixin PMI
European stocks mixed; Lagarde speech, Fed minutes in focus
WeWork plans to file for bankruptcy as early as next week - source
Weak yen, inflation overshoot may prod BOJ to phase out stimulus by year-end: ex-BOJ official
Turkish manufacturing activity contracts in October - PMI
Bayer ordered to pay $332 million in Roundup cancer trial
